aga

¿Biológico o Biosimilar?

No importa cuál.

He aquí la razón.

Rigurosos procesos de aprobación

La FDA analiza cuidadosamente todos los productos biológicos

Demostrado con el tiempo

Usado durante más de 15 años para tratar más de 12 enfermedades[1]



Los biosimilares SON biológicos

Mismo medicamento, diferente marca

Resultados exitosos del tratamiento

Docenas de estudios muestran que la eficacia y la inocuidad son las mismas[2–27]



Altos estándares de fabricación

Ambos se fabrican de la misma manera

Acceso y apoyo al paciente

Programas sólidos disponibles con todas las marcas

En resumen: Comenzar y permanecer en terapia es clave, y los biosimilares no son un peligro. Puede sentirse seguro acerca de su tratamiento sin importar qué marca se seleccione.

FDA = Administración de Alimentos y Medicamentos de los Estados Unidos.

Bibliografía:

1. Padda, I.S., Bhatt, R., Rehman, O. et al. Biosimilars use in medicine for inflammatory diseases. Updated 2022 Jan 6. In: StatPearls [internet]. Treasure Island, FL: StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK574572/#_NBK574572_pubdet_.
2. Schellekens, H., Smolen, J.S., Dicato, M. et al. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016;17:e502–e509.
3. Howden, C.W., Lichtenstein, G.R. Meeting report: AGA biosimilars roundtable. Gastroenterology. 2018;154:e1–e5.
4. Weise, M., Kurki, P., Wolff-Holz, E. et al. Biosimilars: The science of extrapolation. Blood. 2014;124:3191–3196.
5. Park, W., Hrycaj, P., Jeka, S. et al. A randomized, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612.
6. Yoo, D.H., Hrycaj, P., Miranda, P. et al. A randomized, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.
7. Park, W., Yoo, D.H., Miranda, P. et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76:346–354.
8. Yoo, D.H., Prodanovic, N., Jaworski, J. et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CTP13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355–363.
9. Fiorino, G., Caprioli, F., Daperno, M. et al. Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2019;51:632–639.
10. Choe, J.Y., Prodanovic, N., Niebrzydowski, J. et al. A randomized, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:58–64.
11. Danese, S., Bonovas, S., Peyrin-Biroulet, L. Biosimilars in IBD: From theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14:22–31.
12. Kay, J., Chopra, A., Chandrashekara, S. et al. AB0420 Secondary efficacy outcomes from a phase 3 study support clinical equivalence between BOW015 and infliximab in patients with active rheumatoid arthritis on stable methotrexate doses. Ann Rheum Dis. 2015;74(Suppl 2):1034.
13. Taylor, P., Wyand, M., Knight, A. et al. FRI0163 Efficacy of the biosimilar BOW015, compared to originator infliximab, initiated at moderate and severe disease activity thresholds in rheumatoid arthritis. Ann Rheum Dis. 2016;75(Suppl 2):488–489.
14. Kay, J., Chopra, A., Lassen, C. et al. FRI0117 BOW015, a biosimilar infliximab: Disease activity and disability outcomes from a phase 3 active comparator study in patients with active rheumatoid arthritis on stable methotrexate doses. Ann Rheum Dis. 2015;73(Suppl 2):462–463.
15. Fiorino, G., Manetti, N., Armuzzi, A. et al. The PROSIT-BIO cohort: A prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23:233–243.
16. Smolen, J.S., Choe, J.Y., Prodanovic, N. et al. Safety, immunogenicity, and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: Results of a randomized, double-blind, phase III transition study. Ann Rheum Dis. 2018;77:234–240.
17. Tanaka, Y., Yamanaka, H., Takeuchi, T. et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27:237–245.
18. Jorgensen, K.K., Olsen, I.C., Goll, G.L. et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomized, double-blind, non-inferiority trial. Lancet. 2017;389:2304–2316.
19. Meyer, A., Rudant, J., Drouin, J. et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: A French equivalence study. Ann Intern Med. 2019;170:99–107.
20. Ye, B.D., Pesegova, M., Alexeeva, O. et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: An international, randomized, double-blind, phase 3 non-inferiority study. Lancet. 2019;393:1699–1707.
21. Goll, G.L., Jørgensen, K.K., Sexton, J. et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285:653–669.
22. Roder, H., Schnitzler, F., Borchardt, J. et al. Switch of infliximab originator to biosimilar CT-P13 in patients with Crohn's disease and ulcerative colitis in a large German IBD center. A one year, randomized and prospective trial (abstract). United European Gastroenterol J. 2018;8:A456.
23. Ilias, A., Szanto, K., Gonczi, L. et al. Outcomes of patients with inflammatory bowel diseases switched from maintenance therapy with a biosimilar to Remicade. Clin Gastroenterol Hepatol. 2019;17:2506–2513.e2.
24. Meyer, A., Rudant, J., Drouin, J. et al. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. Aliment Pharmacol Ther. 2019;50:269–277.
25. Glintborg, B., Sørensen, I.J., Loft, A.G. et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76:1426–1431.
26. Strik, A.S., van de Vrie, W., Bloemsaat-Minekus, J.P.J. et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): An open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018;3:404-412.
27. Blauvelt, A., Lacour, J.P., Fowler, J.F. Jr. et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: Impact of multiple switches. Br J Dermatol. 2018;179:623–631.

Amgen y Pfizer Inc., provee financiación educativa para apoyar esta actividad.